Logo

MGRX

Mangoceuticals, Inc.

MGRX

Mangoceuticals, Inc. • NASDAQ
$1.11 ▲ 3.74% (+0.04)
Market Cap $12.69 M
52w High $6.15
52w Low $0.98
Dividend Yield 0%
P/E -0.41
Volume 192.77K
Outstanding Shares 11.44M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $84.246K ▼ $7.594M ▲ $-7.618M ▼ -9.043K% ▼ $-0.69 ▼ $-7.518M ▼
Q2-2025 $168.109K ▲ $5.358M ▲ $-5.416M ▼ -3.222K% ▲ $-0.54 ▲ $-4.558M ▼
Q1-2025 $109.306K ▲ $4.915M ▲ $-4.839M ▼ -4.427K% ▼ $-1.054 ▼ $-4.438M ▼
Q4-2024 $105.247K ▼ $1.758M ▼ $-1.948M ▲ -1.851K% ▼ $-0.6 ▲ $-1.677M ▲
Q3-2024 $133.368K $1.841M $-1.999M -1.499K% $-0.993 $-1.758M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $481.281K ▲ $16.532M ▼ $804.275K ▼ $15.729M ▼
Q2-2025 $101.019K ▲ $20.843M ▼ $1.601M ▲ $19.243M ▼
Q1-2025 $76.496K ▲ $21.754M ▲ $1.503M ▲ $20.252M ▲
Q4-2024 $58.653K ▼ $15.371M ▲ $1.425M ▲ $13.946M ▲
Q3-2024 $73.912K $14.792M $1.404M $13.389M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-7.618M ▼ $-1.241M ▲ $0 $1.622M ▲ $380.262K ▲ $-1.241M ▲
Q2-2025 $-5.416M ▼ $-1.256M ▲ $0 $1.281M ▼ $24.523K ▲ $-1.256M ▲
Q1-2025 $-4.839M ▼ $-2.275M ▼ $0 $2.285M ▲ $17.843K ▲ $-2.275M ▼
Q4-2024 $-1.949M ▲ $-1.13M ▲ $0 $1.122M ▲ $-15.259K ▲ $-1.13M ▲
Q3-2024 $-2M $-1.166M $0 $750K $-416.331K $-1.166M

Five-Year Company Overview

Income Statement

Income Statement Mangoceuticals looks very early-stage from an income perspective. Reported revenue is essentially nonexistent so far, while operating losses and net losses are consistent. Earnings per share are deeply negative, reflecting sizable losses spread over a very small economic base. This suggests the business is still in the build-out phase: spending ahead of meaningful sales, testing products and marketing, and trying to gain traction in its target markets rather than operating as a mature, revenue-generating healthcare platform.

Balance Sheet

Balance Sheet The balance sheet appears very thin, with only a small pool of assets and equity and no meaningful reported debt. This kind of structure is typical for a young, development-focused company but also means there is limited financial cushion if results or funding conditions worsen. The lack of visible cash in the summary data raises questions about how operations are currently financed and how much runway the company truly has, making external capital raises and careful cost control important ongoing considerations.

Cash Flow

Cash Flow Cash flow patterns are consistent with an early-stage, loss-making company: operating cash flow has been negative, and there is effectively no capital spending shown. That implies the main cash use is funding operating expenses such as technology, marketing, payroll, and regulatory work, rather than building large physical assets. While absolute cash burn may be small compared with larger healthcare players, the company’s modest size makes any ongoing outflows significant. Sustainably covering this burn will likely depend on raising capital or rapidly scaling revenue over time.

Competitive Edge

Competitive Edge Mangoceuticals is trying to carve out a niche in men’s (and increasingly women’s) wellness within the broader telehealth space. Its differentiation rests on convenience, direct-to-consumer access, and a brand built around sensitive, lifestyle-oriented conditions like sexual health, hair loss, hormone balance, and weight management. The telemedicine platform, discrete shipping, and focus on compounded and customized medications provide some differentiation versus generic online pharmacies. However, the markets it targets—telehealth, wellness, GLP-1 weight loss, and oral stimulant pouches—are crowded and fast-moving, with larger, better-capitalized competitors. The company’s challenge is to turn its brand and product variety into durable customer relationships and recurring revenue before competitors or regulatory shifts erode its edge.

Innovation and R&D

Innovation and R&D Innovation is the clear focal point of the strategy. Mangoceuticals is blending a proprietary telehealth platform with novel dosage forms and multi-ingredient formulations, such as chewable or dissolvable products combining several active components into a single, more user-friendly treatment. The company is also building a portfolio of intellectual property through acquisitions: preventive oral care technologies, mushroom-based wellness compositions, and smokeless oral stimulant pouch technology. On top of that, its DEA-approved telemedicine system and move into GLP-1 weight-loss prescribing show an effort to sit at the intersection of regulated medicine and consumer wellness. The upside is a potentially broad product pipeline and multiple growth avenues; the risk is execution complexity, regulatory scrutiny, and the need for meaningful marketing and clinical validation to stand out in skeptical and highly regulated health markets.

Summary

Overall, Mangoceuticals is a very early-stage telehealth and wellness company focused on innovation and brand-building rather than current financial strength. The financials show minimal revenue and persistent losses, with a lean balance sheet and negative operating cash flow, all of which highlight funding and execution risk. At the same time, the business is pursuing a differentiated mix of telemedicine technology, niche wellness brands, and acquired IP across oral care, hormone health, weight loss, and stimulant pouches. The longer-term story hinges on whether the company can turn its pipeline and platform into sustainable, scaled revenue before capital constraints, competition, or regulation limit its options.

NEWS

November 13, 2025 · 7:37 PM UTC

Mangoceuticals Provides Clarification on Launch of Branded GLP-1 Weight-Management Programs

Read more